Myriad Genetics Adds 15 Clinically Actionable Genes to MyRisk® Hereditary Cancer Test to Support Evolving Clinical Needs

Core Insights - Myriad Genetics has expanded its MyRisk Hereditary Cancer Test to include 100% of genes strongly recommended by national oncology guidelines, enhancing its position in molecular diagnostic testing [1][2][3] Group 1: Test Expansion and Clinical Relevance - The updated MyRisk panel now includes 63 selected genes associated with over 11 cancer types, reflecting the company's commitment to evolving clinical needs [2] - The MyRisk Test is designed to provide clinical value throughout the cancer care continuum, aiding in treatment decisions, surveillance planning, and family risk assessment [3] Group 2: Company Commitment and Expertise - Myriad Genetics emphasizes its expertise in interpreting DNA variants, which significantly impacts patient care, prioritizing genes that influence treatment decisions [3] - The company aims to provide high clinical utility insights to clinicians and genetic counselors, ensuring that the MyRisk Test remains relevant as guidelines evolve [3] Group 3: Accessibility and Integration - Clinicians can conveniently order and review MyRisk Test results through various platforms, including paper forms, the Myriad patient portal, and electronic medical record systems like EPIC and OncoEMR [3]